Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS18
PHASE 3 / 2-34
RECRUITING13
READOUTS ≤12 MONTHS9
READOUT SLIPPED >6 MO21%
Delay Index: of 14 active trials registered more than a year ago, 3 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →
Open Suzhou Zelgen Biopharmaceuticals Co.,Ltd on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| ZG006 NCT06440057 |
P1/2 | Recruiting | Neuroendocrine Carcinoma | 78 | 2026-05 |
| ZG006 NCT05978284 |
P1/2 | Recruiting | Small Cell Lung Cancer; Neuroendocrine Carcinoma | 54 | 2026-09 (+12 mo) |
| ZGGS18 for Injection NCT05584800 |
P1/2 | Recruiting | Advanced Solid Tumor | 222 | 2026-11-01 (+36 mo) |
| ZG005 for Injection NCT06883526 |
P1/2 | Recruiting | Lymphoma | 60 | 2027-04 |
| ZG005 for Injection NCT06903377 |
P1/2 | Recruiting | Non-small Cell Lung Cancer | 50 | 2027-04 |
| ZG006 NCT06283719 |
P1/2 | Recruiting | Small Cell Lung Cancer; Neuroendocrine Cancer | 265 | 2027-04 (+12 mo) |
| ZGGS18 for Injection NCT06938880 |
P1/2 | Recruiting | Advanced Solid Tumor | 60 | 2027-05 |
| ZG005 for Injection NCT06927687 |
P2 | Active, not recruiting | Advanced Solid Tumor | 50 | 2027-05 |
| ZG005 NCT07080216 |
P1/2 | Recruiting | Cervical Cancer | 120 | 2027-08 |
| ZG006 NCT07038096 |
P1/2 | Recruiting | Small Cell Lung Cancer; Neuroendocrine Carcinoma | 350 | 2027-09 |
| ZG005 NCT07142837 |
P1/2 | Not yet recruiting | Advanced Solid Tumor | 153 | 2027-10 |
| ZG005 NCT07099547 |
P2 | Recruiting | Biliary Tract Carcinoma | 60 | 2027-12 |
| ZG006 NCT07024277 |
P2 | Not yet recruiting | Neuroendocrine Prostate Cancer | 60 | 2027-12 |
| ZG006 NCT07595913 |
P3 | Not yet recruiting | Neuroendocrine Carcinoma | 240 | 2028-06 |
| ZG006 NCT07189455 |
P3 | Recruiting | Small-cell Lung Cancer | 420 | 2028-10 |
| ZG006 NCT07258121 |
P1/2 | Recruiting | Solid Tumor | 400 | 2028-12 |
| ZG005 for Injection NCT07813572 |
P3 | Recruiting | Hepatocellular Carcinoma | 600 | 2031-09 |
| ZG005 for Injection NCT07833839 |
P3 | Not yet recruiting | Neuroendocrine Carcinomas (NEC) | 440 | 2031-10 |